https://zedie.org/2011/12/12/new-phase-iii-data-shows-novartis-jak-inhibitor-inc424-significantly-reduced-disease-burden-in-patients-with-myelofibrosis/
New Phase III data shows Novartis JAK inhibitor INC424 significantly reduced disease burden in patients with myelofibrosis